Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 20 entries
Sorted by: Best Match Show Resources per page
Future perspectives in glaucoma medical therapy.

Archivos de la Sociedad Espanola de Oftalmologia

Martinez-de-la-Casa JM.
PMID: 29137824
Arch Soc Esp Oftalmol (Engl Ed). 2018 Jan;93(1):1-2. doi: 10.1016/j.oftal.2017.09.009. Epub 2017 Nov 11.

No abstract available.

Cite
Martinez-de-la-Casa JM. Perspectivas futuras en el tratamiento médico del glaucoma. Future perspectives in glaucoma medical therapy. Arch Soc Esp Oftalmol (Engl Ed). 2017;93(1):1-2doi: 10.1016/j.oftal.2017.09.009.
Martinez-de-la-Casa, J. M. (2018). Perspectivas futuras en el tratamiento médico del glaucoma. Future perspectives in glaucoma medical therapy. Archivos de la Sociedad Espanola de Oftalmologia, 93(1), 1-2. https://doi.org/10.1016/j.oftal.2017.09.009
Martinez-de-la-Casa, J M. "Perspectivas futuras en el tratamiento médico del glaucoma." Future perspectives in glaucoma medical therapy. Archivos de la Sociedad Espanola de Oftalmologia vol. 93,1 (2018): 1-2. doi: https://doi.org/10.1016/j.oftal.2017.09.009
Martinez-de-la-Casa JM. Perspectivas futuras en el tratamiento médico del glaucoma. Future perspectives in glaucoma medical therapy. Arch Soc Esp Oftalmol (Engl Ed). 2018 Jan;93(1):1-2. doi: 10.1016/j.oftal.2017.09.009. Epub 2017 Nov 11. Spanish. PMID: 29137824.
Copy Download .nbib Format: NLM
New perspectives in glaucoma.

Medicine and health, Rhode Island

Murphy SD.
PMID: 10030117
Med Health R I. 1999 Feb;82(2):58-61.

No abstract available.

Cite
Murphy SD. New perspectives in glaucoma. Med Health R I. 1999;82(2):58-61
Murphy, S. D. (1999). New perspectives in glaucoma. Medicine and health, Rhode Island, 82(2), 58-61.
Murphy, S D. "New perspectives in glaucoma." Medicine and health, Rhode Island vol. 82,2 (1999): 58-61.
Murphy SD. New perspectives in glaucoma. Med Health R I. 1999 Feb;82(2):58-61. PMID: 10030117.
Copy Download .nbib Format: NLM
Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

El Hoffy NM, Abdel Azim EA, Hathout RM, Fouly MA, Elkheshen SA.
PMID: 33227347
Eur J Pharm Sci. 2021 Mar 01;158:105648. doi: 10.1016/j.ejps.2020.105648. Epub 2020 Nov 21.

Glaucoma, being asymptomatic for relatively late stage, is recognized as a worldwide cause of irreversible vision loss. The eye is an impervious organ that exhibits natural anatomical and physiological barriers which renders the design of an efficient ocular delivery...

Cite
El Hoffy NM, Abdel Azim EA, Hathout RM, et al. Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities. Eur J Pharm Sci. 2020;158:105648doi: 10.1016/j.ejps.2020.105648.
El Hoffy, N. M., Abdel Azim, E. A., Hathout, R. M., Fouly, M. A., & Elkheshen, S. A. (2021). Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 158105648. https://doi.org/10.1016/j.ejps.2020.105648
El Hoffy, Nada M, et al. "Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities." European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences vol. 158 (2021): 105648. doi: https://doi.org/10.1016/j.ejps.2020.105648
El Hoffy NM, Abdel Azim EA, Hathout RM, Fouly MA, Elkheshen SA. Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities. Eur J Pharm Sci. 2021 Mar 01;158:105648. doi: 10.1016/j.ejps.2020.105648. Epub 2020 Nov 21. PMID: 33227347.
Copy Download .nbib Format: NLM
A comprehensive map of disease networks and molecular drug discoveries for glaucoma.

Scientific reports

Wang H, Deng Y, Wan L, Huang L.
PMID: 32546683
Sci Rep. 2020 Jun 16;10(1):9719. doi: 10.1038/s41598-020-66350-w.

Glaucoma is the leading cause of irreversible blindness worldwide. The molecular etiology of glaucoma is complex and unclear. At present, there are few drugs available for glaucoma treatment. The aim of the present study was to perform a systematic...

Cite
Wang H, Deng Y, Wan L, et al. A comprehensive map of disease networks and molecular drug discoveries for glaucoma. Sci Rep. 2020;10(1):9719doi: 10.1038/s41598-020-66350-w.
Wang, H., Deng, Y., Wan, L., & Huang, L. (2020). A comprehensive map of disease networks and molecular drug discoveries for glaucoma. Scientific reports, 10(1), 9719. https://doi.org/10.1038/s41598-020-66350-w
Wang, Haixin, et al. "A comprehensive map of disease networks and molecular drug discoveries for glaucoma." Scientific reports vol. 10,1 (2020): 9719. doi: https://doi.org/10.1038/s41598-020-66350-w
Wang H, Deng Y, Wan L, Huang L. A comprehensive map of disease networks and molecular drug discoveries for glaucoma. Sci Rep. 2020 Jun 16;10(1):9719. doi: 10.1038/s41598-020-66350-w. PMID: 32546683; PMCID: PMC7298047.
Copy Download .nbib Format: NLM
Understanding glaucoma.

Nursing mirror

Shreeve C.
PMID: 3846259
Nurs Mirror. 1985 Apr 24;160(17):18-9.

No abstract available.

Cite
Shreeve C. Understanding glaucoma. Nurs Mirror. 1985;160(17):18-9
Shreeve, C. (1985). Understanding glaucoma. Nursing mirror, 160(17), 18-9.
Shreeve, C. "Understanding glaucoma." Nursing mirror vol. 160,17 (1985): 18-9.
Shreeve C. Understanding glaucoma. Nurs Mirror. 1985 Apr 24;160(17):18-9. PMID: 3846259.
Copy Download .nbib Format: NLM
[Pathogenesis, symptomatology, medical treatment of closed-angle glaucoma].

Bulletin de la Societe belge d'ophtalmologie

Collignon-Brach J, Demailly P, Etienne R, Grieten J, Weekers R.
PMID: 614887
Bull Soc Belge Ophtalmol. 1977;(177):79-99.

No abstract available.

Cite
Collignon-Brach J, Demailly P, Etienne R, et al. Pathogénie, sémiologie, traitment médical du glaucome à angle fermé. [Pathogenesis, symptomatology, medical treatment of closed-angle glaucoma]. Bull Soc Belge Ophtalmol. 1977;(177):79-99
Collignon-Brach, J., Demailly, P., Etienne, R., Grieten, J., & Weekers, R. (1977). Pathogénie, sémiologie, traitment médical du glaucome à angle fermé. [Pathogenesis, symptomatology, medical treatment of closed-angle glaucoma]. Bulletin de la Societe belge d'ophtalmologie, (177), 79-99.
Collignon-Brach, J, et al. "Pathogénie, sémiologie, traitment médical du glaucome à angle fermé." [Pathogenesis, symptomatology, medical treatment of closed-angle glaucoma]. Bulletin de la Societe belge d'ophtalmologie vol. ,177 (1977): 79-99.
Collignon-Brach J, Demailly P, Etienne R, Grieten J, Weekers R. Pathogénie, sémiologie, traitment médical du glaucome à angle fermé. [Pathogenesis, symptomatology, medical treatment of closed-angle glaucoma]. Bull Soc Belge Ophtalmol. 1977;(177):79-99. French. PMID: 614887.
Copy Download .nbib Format: NLM
The glaucomas.

Pennsylvania medicine

Richardson KT.
PMID: 5797003
Pa Med. 1969 May;72(5):61-4.

No abstract available.

Cite
Richardson KT. The glaucomas. Pa Med. 1969;72(5):61-4
Richardson, K. T. (1969). The glaucomas. Pennsylvania medicine, 72(5), 61-4.
Richardson, K T. "The glaucomas." Pennsylvania medicine vol. 72,5 (1969): 61-4.
Richardson KT. The glaucomas. Pa Med. 1969 May;72(5):61-4. PMID: 5797003.
Copy Download .nbib Format: NLM
Newer therapeutic vistas for antiglaucoma medicines.

Critical reviews in therapeutic drug carrier systems

Kaur IP, Kakkar S.
PMID: 21663575
Crit Rev Ther Drug Carrier Syst. 2011;28(2):165-202. doi: 10.1615/critrevtherdrugcarriersyst.v28.i2.20.

Glaucoma is second to cataract as a leading cause of global blindness and is the leading cause of irreversible visual loss. By the year 2020, almost 80 million people are estimated to be affected with open-angle glaucoma and angle-closure...

Cite
Kaur IP, Kakkar S. Newer therapeutic vistas for antiglaucoma medicines. Crit Rev Ther Drug Carrier Syst. 2011;28(2):165-202doi: 10.1615/critrevtherdrugcarriersyst.v28.i2.20.
Kaur, I. P., & Kakkar, S. (2011). Newer therapeutic vistas for antiglaucoma medicines. Critical reviews in therapeutic drug carrier systems, 28(2), 165-202. https://doi.org/10.1615/critrevtherdrugcarriersyst.v28.i2.20
Kaur, Indu Pal, and Kakkar, Shilpa. "Newer therapeutic vistas for antiglaucoma medicines." Critical reviews in therapeutic drug carrier systems vol. 28,2 (2011): 165-202. doi: https://doi.org/10.1615/critrevtherdrugcarriersyst.v28.i2.20
Kaur IP, Kakkar S. Newer therapeutic vistas for antiglaucoma medicines. Crit Rev Ther Drug Carrier Syst. 2011;28(2):165-202. doi: 10.1615/critrevtherdrugcarriersyst.v28.i2.20. PMID: 21663575.
Copy Download .nbib Format: NLM
[Medical treatments and practices. Ascertaining maximal drug treatment].

Journal francais d'ophtalmologie

Cochereau I.
PMID: 16208241
J Fr Ophtalmol. 2005 Jun;28:2S45-2S47.

Maximal drug treatment can be absolute, using all the combinations possible if no surgery can reasonably be undertaken, or relative, with surgery as the next step. The drug treatment is chosen in collaboration with the patient, who should always...

Cite
Cochereau I. Traitements médicaux. Quel doit être un "traitement médical maximal"? [Medical treatments and practices. Ascertaining maximal drug treatment]. J Fr Ophtalmol. 2005;28:2S45-2S47
Cochereau, I. (2005). Traitements médicaux. Quel doit être un "traitement médical maximal"? [Medical treatments and practices. Ascertaining maximal drug treatment]. Journal francais d'ophtalmologie, 282S45-2S47.
Cochereau, I. "Traitements médicaux. Quel doit être un "traitement médical maximal"?" [Medical treatments and practices. Ascertaining maximal drug treatment]. Journal francais d'ophtalmologie vol. 28 (2005): 2S45-2S47.
Cochereau I. Traitements médicaux. Quel doit être un "traitement médical maximal"? [Medical treatments and practices. Ascertaining maximal drug treatment]. J Fr Ophtalmol. 2005 Jun;28:2S45-2S47. French. PMID: 16208241.
Copy Download .nbib Format: NLM
Glaucoma detection.

Ophthalmology

Weene L.
PMID: 17613334
Ophthalmology. 2007 Jul;114(7):1414. doi: 10.1016/j.ophtha.2007.03.060.

No abstract available.

Cite
Weene L. Glaucoma detection. Ophthalmology. 2007;114(7):1414doi: 10.1016/j.ophtha.2007.03.060.
Weene, L. (2007). Glaucoma detection. Ophthalmology, 114(7), 1414. https://doi.org/10.1016/j.ophtha.2007.03.060
Weene, Lawrence. "Glaucoma detection." Ophthalmology vol. 114,7 (2007): 1414. doi: https://doi.org/10.1016/j.ophtha.2007.03.060
Weene L. Glaucoma detection. Ophthalmology. 2007 Jul;114(7):1414. doi: 10.1016/j.ophtha.2007.03.060. PMID: 17613334.
Copy Download .nbib Format: NLM
[Glaucoma: pharmacological implications].

Semergen

Rieger-Reyes C, Rubio-Galán FJ.
PMID: 23517894
Semergen. 2013 Jan-Feb;39(1):26-33. doi: 10.1016/j.semerg.2012.05.003. Epub 2012 Sep 05.

Glaucoma is the first cause of irreversible blindness worldwide. Its prevalence in our country is 2%; half of patients remain undiagnosed. Certain drugs can trigger and/or exacerbate glaucoma; hence the importance of having knowledge of these drugs by Primary...

Cite
Rieger-Reyes C, Rubio-Galán FJ. Glaucoma: implicaciones farmacológicas. [Glaucoma: pharmacological implications]. Semergen. 2012;39(1):26-33doi: 10.1016/j.semerg.2012.05.003.
Rieger-Reyes, C., & Rubio-Galán, F. J. (2013). Glaucoma: implicaciones farmacológicas. [Glaucoma: pharmacological implications]. Semergen, 39(1), 26-33. https://doi.org/10.1016/j.semerg.2012.05.003
Rieger-Reyes, C, and Rubio-Galán, F J. "Glaucoma: implicaciones farmacológicas." [Glaucoma: pharmacological implications]. Semergen vol. 39,1 (2013): 26-33. doi: https://doi.org/10.1016/j.semerg.2012.05.003
Rieger-Reyes C, Rubio-Galán FJ. Glaucoma: implicaciones farmacológicas. [Glaucoma: pharmacological implications]. Semergen. 2013 Jan-Feb;39(1):26-33. doi: 10.1016/j.semerg.2012.05.003. Epub 2012 Sep 05. Spanish. PMID: 23517894.
Copy Download .nbib Format: NLM
Glaucoma and glaucoma medications.

Orthopedic nursing

Turkoski BB.
PMID: 22278651
Orthop Nurs. 2012 Jan-Feb;31(1):37-41. doi: 10.1097/NOR.0b013e31824196a8.

Glaucoma is an insidious "thief of vision" that affects millions of Americans and is a leading cause of blindness worldwide. The signs of the most common form of glaucoma are incremental and are often not noticed until the vision...

Cite
Turkoski BB. Glaucoma and glaucoma medications. Orthop Nurs. 2012;31(1):37-41doi: 10.1097/NOR.0b013e31824196a8.
Turkoski, B. B. (2012). Glaucoma and glaucoma medications. Orthopedic nursing, 31(1), 37-41. https://doi.org/10.1097/NOR.0b013e31824196a8
Turkoski, Beatrice B. "Glaucoma and glaucoma medications." Orthopedic nursing vol. 31,1 (2012): 37-41. doi: https://doi.org/10.1097/NOR.0b013e31824196a8
Turkoski BB. Glaucoma and glaucoma medications. Orthop Nurs. 2012 Jan-Feb;31(1):37-41. doi: 10.1097/NOR.0b013e31824196a8. PMID: 22278651.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 20 entries